Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
Source abstract
Abstract
TP53 is the most frequently mutated or deleted gene in triple negative breast cancer (TNBC). Both the loss of TP53 and the lack of targeted therapy are significantly correlated with poor clinical outcomes, making TNBC the only type of breast cancer that has no approved targeted therapies. Through in silico analysis, we identified POLR2A in the TP53-neighbouring region as a collateral vulnerability target in TNBC tumours, suggesting that its inhibition via small interfering RNA (siRNA) may be an amenable approach for TNBC targeted treatment. To enhance bioavailability and improve endo/lysosomal escape of siRNA, we designed pH-activated nanoparticles for augmented cytosolic delivery of POLR2A siRNA (siPol2). Suppression of POLR2A expression with the siPol2-laden nanoparticles leads to enhanced growth reduction of tumours characterized by hemizygous POLR2A loss. These results demonstrate the potential of the pH-responsive nanoparticle and the precise POLR2A targeted therapy in TNBC harbouring the common TP53 genomic alteration.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Virus-based gene therapy research · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434 (2007).10.1158/1078-0432.CCR-06-3045 ↗
2. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938–1948 (2010).10.1056/NEJMra1001389 ↗
3. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395–399 (2012).10.1038/nature10933 ↗
4. Denkert, C., Liedtke, C., Tutt, A. & von Minckwitz, G. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. Lancet 389, 2430–2442 (2017).10.1016/S0140-6736(16)32454-0 ↗
5. Mayer, E. L. & Burstein, H. J. Chemotherapy for triple-negative breast cancer: is more better? J. Clin. Oncol. 34, 3369–3371 (2016).10.1200/JCO.2016.68.4068 ↗
6. Chin, L., Hahn, W. C., Getz, G. & Meyerson, M. Making sense of cancer genomic data. Gene Dev. 25, 534–555 (2011).10.1101/gad.2017311 ↗
7. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).10.1126/science.1235122 ↗
8. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).10.1016/j.ccr.2010.05.026 ↗
9. Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674–690 (2016).10.1038/nrclinonc.2016.66 ↗
10. Weisman, P. S. et al. Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Mod. Pathol. 29, 476–488 (2016).10.1038/modpathol.2016.39 ↗
11. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007).10.1038/nature05541 ↗
12. Olivier, M. et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607–614 (2002).10.1002/humu.10081 ↗
13. Joerger, A. C. & Fersht, A. R. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu. Rev. Biochem. 85, 375–404 (2016).10.1146/annurev-biochem-060815-014710 ↗
14. Liu, Y. et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 520, 697–701 (2015).10.1038/nature14418 ↗
15. Clark, V. E. et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat. Genet. 48, 1253–1259 (2016).10.1038/ng.3651 ↗
16. Novina, C. D. & Sharp, P. A. The RNAi revolution. Nature 430, 161–164 (2004).10.1038/430161a ↗
17. Liang, C. et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat. Med. 21, 288–294 (2015).10.1038/nm.3791 ↗
18. Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13, 828–851 (2014).
19. Paul, C. P., Good, P. D., Winer, I. & Engelke, D. R. Effective expression of small interfering RNA in human cells. Nat. Biotechnol. 20, 505–508 (2002).
20. Morris, K. V., Chan, S. W.-L., Jacobsen, S. E. & Looney, D. J. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305, 1289–1292 (2004).10.1126/science.1101372 ↗
21. Kumar, P. et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39–43 (2007).10.1038/nature05901 ↗
22. Wittrup, A. & Lieberman, J. Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet. 16, 543–552 (2015).10.1038/nrg3978 ↗
23. Bobbin, M. L. & Rossi, J. J. RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu. Rev. Pharmacol. Toxicol. 56, 103–122 (2016).10.1146/annurev-pharmtox-010715-103633 ↗
24. Dahlman, J. E. et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol. 9, 648–655 (2014).
25. Zuckerman, J. E. & Davis, M. E. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 14, 843–856 (2015).10.1038/nrd4685 ↗
26. Wang, H. et al. A near‐infrared laser‐activated ‘nanobomb’ for breaking the barriers to microRNA delivery. Adv. Mater. 28, 347–355 (2016).10.1002/adma.201504263 ↗
27. Cui, J. et al. Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells. Nat. Commun. 8, 191 (2017).
28. Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7, 389–393 (2012).
29. Kong, H. J. & Mooney, D. J. Microenvironmental regulation of biomacromolecular therapies. Nat. Rev. Drug Discov. 6, 455–463 (2007).10.1038/nrd2309 ↗
30. Shu, D. et al. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 9, 9731–9740 (2015).10.1021/acsnano.5b02471 ↗
31. Adams, B. D. et al. miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer. Cancer Res. 76, 927–939 (2016).10.1158/0008-5472.CAN-15-2321 ↗
32. Guo, X. & Huang, L. Recent advances in nonviral vectors for gene delivery. Acc. Chem. Res. 45, 971–979 (2012).10.1021/ar200151m ↗
33. Zhou, J. et al. Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nat. Mater. 11, 82–90 (2011).
34. Wang, H., Yu, J., Lu, X. & He, X. Nanoparticle systems reduce systemic toxicity in cancer treatment. Nanomedicine 11, 103–106 (2016).10.2217/nnm.15.166 ↗
35. Farokhzad, O. C. & Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 3, 16–20 (2009).10.1021/nn900002m ↗
36. Lu, Y., Aimetti, A. A., Langer, R. & Gu, Z. Bioresponsive materials. Nat. Rev. Mater. 2, 16075 (2016).10.1038/natrevmats.2016.75 ↗
37. Kim, H. J., Kim, A., Miyata, K. & Kataoka, K. Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv. Drug Deliv. Rev. 104, 61–77 (2016).10.1016/j.addr.2016.06.011 ↗
38. El Andaloussi, S., Mäger, I., Breakefield, X. O. & Wood, M. J. A. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12, 347–357 (2013).10.1038/nrd3978 ↗
39. Maas, S. L. N., Breakefield, X. O. & Weaver, A. M. Extracellular vesicles: unique intercellular delivery vehicles. Trends Cell Biol. 27, 172–188 (2017).10.1016/j.tcb.2016.11.003 ↗
40. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341–345 (2011).10.1038/nbt.1807 ↗
41. Zhao, Y. et al. Polymetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nat. Commun. 7, 11822 (2016).
42. Seipp, C. A., Williams, N. J., Kidder, M. K. & Custelcean, R. CO2 capture from ambient air by crystallization with a guanidine sorbent. Angew. Chem. Int. Ed. 56, 1042–1045 (2017).10.1002/anie.201610916 ↗
43. Manders, E. M. M., Verbeek, F. J. & Aten, J. A. Measurement of co-localization of objects in dual-colour confocal images. J. Microsc. 169, 375–382 (1993).10.1111/j.1365-2818.1993.tb03313.x ↗
44. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).10.1038/natrevmats.2016.14 ↗
45. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352 (2012).10.1038/nature10983 ↗
46. Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun 7, 11479 (2016).10.1038/ncomms11479 ↗
47. Ciriello, G. et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163, 506–519 (2015).10.1016/j.cell.2015.09.033 ↗
48. Wang, H. et al. Multi-layered polymeric nanoparticles for pH-responsive and sequenced release of theranostic agents. Chem. Commun. 51, 7733–7736 (2015).10.1039/C5CC01833A ↗